-+ 0.00%
-+ 0.00%
-+ 0.00%

Candel Publishes Final Phase Of 2a Clinical Trial Results Of of Aglatimagene Besadenovec Plus Valacyclovir In Patients With Stage III/IV NSCLC Showing Inadequate Response To ICI.

Benzinga·10/01/2026 12:11:03
Listen to the news

Peer-reviewed publication in Journal for ImmunoTherapy of Cancer reports median overall survival of 24.5 months in advanced non-small cell lung cancer (NSCLC) patients with inadequate response to immune checkpoint inhibitors (ICI)